Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Bridget O'rourke sold 50 shares of Penumbra stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $285.48, for a total value of $14,274.00. Following the completion of the transaction, the director now owns 5,573 shares of the company's stock, valued at approximately $1,590,980.04. This represents a 0.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Penumbra Stock Performance
Shares of PEN stock opened at $285.91 on Thursday. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $265.94 and a 200 day moving average price of $234.26. The company has a market cap of $11.01 billion, a P/E ratio of 840.91, a PEG ratio of 2.83 and a beta of 0.53. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00.
Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. Sell-side analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on Penumbra from $275.00 to $305.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Citigroup upped their price target on Penumbra from $220.00 to $245.00 and gave the company a "neutral" rating in a research report on Wednesday, December 11th. Truist Financial boosted their price objective on Penumbra from $285.00 to $325.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. raised their target price on Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Finally, Needham & Company LLC restated a "hold" rating on shares of Penumbra in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Penumbra currently has a consensus rating of "Moderate Buy" and a consensus target price of $292.64.
Check Out Our Latest Report on PEN
Hedge Funds Weigh In On Penumbra
Several large investors have recently bought and sold shares of PEN. Janus Henderson Group PLC boosted its stake in shares of Penumbra by 128.1% during the third quarter. Janus Henderson Group PLC now owns 668,873 shares of the company's stock worth $129,967,000 after buying an additional 375,684 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Penumbra by 3,832.3% during the third quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company's stock worth $71,564,000 after buying an additional 358,932 shares during the period. Champlain Investment Partners LLC boosted its stake in shares of Penumbra by 20.6% during the third quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company's stock worth $300,786,000 after buying an additional 264,122 shares during the period. Norges Bank purchased a new position in Penumbra during the fourth quarter worth about $54,396,000. Finally, T. Rowe Price Investment Management Inc. raised its holdings in Penumbra by 47.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company's stock worth $167,913,000 after purchasing an additional 227,506 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.
About Penumbra
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
